Acute versus long-term effects of 6-hydroxydopamine on oxidative stress and dopamine depletion in the striatum of mice

Journal of Neuroscience Methods

Volumn 202, Issue 2, 2011, Pages 128-136

  Varcin, Mustafa ^a   Bentea, Eduard ^a   Mertens, Birgit ^a   Van Den Haute, Chris ^b   Baekelandt, Veerle ^b   Michotte, Yvette ^a   Sarre, Sophie ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

6 Hydroxydopamine; Mice; Microdialysis; Oxidative stress; Salicylate trapping; Striatum

Indexed keywords

2 CYCLOHEXENONE; 2,3 DIHYDROXYBENZOIC ACID; DOPAMINE; GLUTATHIONE; HYDROXYL RADICAL; OXIDOPAMINE; SALICYLIC ACID; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOREACTIVITY; IN VIVO STUDY; MICRODIALYSIS; MICROENVIRONMENT; MOUSE; NERVE ENDING; NONHUMAN; OXIDATIVE STRESS; PERFUSION; PRIORITY JOURNAL; VALIDATION PROCESS;

ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; CORPUS STRIATUM; DOPAMINE; FEMALE; MICE; MICE, INBRED C57BL; MICRODIALYSIS; NEUROTOXINS; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSONIAN DISORDERS; TIME;

EID: 81055157032     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2011.07.004     Document Type: Article

References (41)

1. Alvarez-Fischer D., Henze C., Strenzke C., Westrich J., Ferger B., Hoglinger G.U., et al. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol 2008, 210:182-193.
2. Aoyama K., Watabe M., Nakaki T. Regulation of neuronal glutathione synthesis. J Pharmacol Sci 2008, 108:227-238.
3. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001, 65:135-172.
4. Camarero J., Sanchez V., O'Shea E., Green A.R., Colado M.I. Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ('ecstasy')-induced dopamine release and free radical formation in the mouse striatum. J Neurochem 2002, 81:961-972.
5. Cheng F.C., Jen J.F., Tsai T.H. Hydroxyl radical in living systems and its separation methods. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 781:481-496.
6. Choy K.H., Dean O., Berk M., Bush A.I., van den Buuse M. Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats. Eur J Pharmacol 2010, 649:224-228.
7. Di Giovanni G., Esposito E., Di Matteo V. In vivo microdialysis in Parkinson's research. J Neural Transm 2009, (Suppl.):223-243.
8. Ferger B., Rose S., Jenner A., Halliwell B., Jenner P. 6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum. Neuroreport 2001, 12:1155-1159.
9. Ferger B., Teismann P., Earl C.D., Kuschinsky K., Oertel W.H. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch Pharmacol 1999, 360:256-261.
10. Ferger B., Teismann P., Mierau J. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res 2000, 883:216-223.
11. Franklin K., Paxinos G. The mouse brain in stereotaxic coordinates 1997, Academic Press, San Diego.
12. Garcia J.C., Remires D., Leiva A., Gonzalez R. Depletion of brain glutathione potentiates the effect of 6-hydroxydopamine in a rat model of Parkinson's disease. J Mol Neurosci 2000, 14:147-153.
13. Goldberg M.S., Fleming S.M., Palacino J.J., Cepeda C., Lam H.A., Bhatnagar A., et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003, 278:43628-43635.
14. Grealish S., Mattsson B., Draxler P., Bjorklund A. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. Eur J Neurosci 2010, 31:2266-2278.
15. Gruber M., Wiesner G., Burger R., Lindner R. The salicylate trapping method: is oxidation of salicylic acid solution oxygen and time dependent and metal catalysed?. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 831:320-323.
16. Iancu R., Mohapel P., Brundin P., Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005, 162:1-10.
17. Jacobsen J.P., Rodriguiz R.M., Mork A., Wetsel W.C. Monoaminergic dysregulation in glutathione-deficient mice: possible relevance to schizophrenia?. Neuroscience 2005, 132:1055-1072.
18. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003, 53(Suppl. 3):S26-S36. [Discussion S-8].
19. Koutsilieri E., Scheller C., Grunblatt E., Nara K., Li J., Riederer P. Free radicals in Parkinson's disease. J Neurol 2002, 249(Suppl. 2):II1-II5.
20. Lu K.T., Ko M.C., Chen B.Y., Huang J.C., Hsieh C.W., Lee M.C., et al. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J Agric Food Chem 2008, 56:6910-6913.
21. Masukawa T., Sai M., Tochino Y. Methods for depleting brain glutathione. Life Sci 1989, 44:417-424.
22. Meredith G.E., Sonsalla P.K., Chesselet M.F. Animal models of Parkinson's disease progression. Acta Neuropathol 2008, 115:385-398.
23. Obata T. Role of hydroxyl radical formation in neurotoxicity as revealed by in vivo free radical trapping. Toxicol Lett 2002, 132:83-93.
24. Obeso J.A., Rodriguez-Oroz M.C., Goetz C.G., Marin C., Kordower J.H., Rodriguez M., et al. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010, 16:653-661.
25. Opacka-Juffry J., Wilson A.W., Blunt S.B. Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum. Brain Res 1998, 810:27-33.
26. Pileblad E., Magnusson T. Effective depletion of glutathione in rat striatum and substantia nigra by l-buthionine sulfoximine in combination with 2-cyclohexene-1-one. Life Sci 1990, 47:2333-2342.
27. Przedborski S. Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat Disord 2005, 11(Suppl 1):S3-S7.
28. Rodriguez-Pallares J., Parga J.A., Munoz A., Rey P., Guerra M.J., Labandeira-Garcia J.L. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J Neurochem 2007, 103:145-156.
29. Rodriguez-Pallares J., Rey P., Parga J.A., Munoz A., Guerra M.J., Labandeira-Garcia J.L. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis 2008, 31:58-73.
30. Schulz J.B., Lindenau J., Seyfried J., Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 2000, 267:4904-4911.
31. Shimizu E., Hashimoto K., Komatsu N., Iyo M. Roles of endogenous glutathione levels on 6-hydroxydopamine-induced apoptotic neuronal cell death in human neuroblastoma SK-N-SH cells. Neuropharmacology 2002, 43:434-443.
32. Smith M.P., Cass W.A. Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease. Neuroscience 2007, 144:1057-1066.
33. Sotnikova T.D., Gainetdinov R.R. Microdialysis in genetically altered animals. Handbook of microdialysis 2007, vol. 16:399-417.
34. Soto-Otero R., Mendez-Alvarez E., Hermida-Ameijeiras A., Munoz-Patino A.M., Labandeira-Garcia J.L. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem 2000, 74:1605-1612.
35. Teismann P., Ferger B. The salicylate hydroxylation assay to measure hydroxyl free radicals induced by local application of glutamate in vivo or induced by the Fenton reaction in vitro. Brain Res Brain Res Protoc 2000, 5:204-210.
36. Themann C., Teismann P., Kuschinsky K., Ferger B. Comparison of two independent aromatic hydroxylation assays in combination with intracerebral microdialysis to determine hydroxyl free radicals. J Neurosci Methods 2001, 108:57-64.
37. Thomas B., Muralikrishnan D., Mohanakumar K.P. In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res 2000, 852:221-224.
38. Tobon-Velasco J.C., Silva-Adaya D., Carmona-Aparicio L., Garcia E., Galvan-Arzate S., Santamaria A. Early toxic effect of 6-hydroxydopamine on extracellular concentrations of neurotransmitters in the rat striatum: an in vivo microdialysis study. Neurotoxicology 2010, 31:715-723.
39. Toulouse A., Sullivan A.M. Progress in Parkinson's disease-where do we stand?. Prog Neurobiol 2008, 85:376-392.
40. Yacoubian T.A., Standaert D.G. Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta 2009, 1792:676-687.
41. Yuan H., Sarre S., Ebinger G., Michotte Y. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease. Brain Res 2004, 1026:95-107.